glenmarkThe effect of financing problem in the US has had on complete Pharma sector, but Glenmark is focusing on the US despite competition. According to the source, the company has focused on Cancer, Breathing, and Skin related medicines. The company has decided to spend 11% of their sales on R&D.

In India the company position is strong and in future the growth will continue.  Sales can not be done in Venezuela, till the condition is not improving. Company debt is continuously decreasing. Further, the income expected to increase 15-20%.

GLENMARK is trading at 936.00 down 0.64%, touched high of 946.45 and low of 928.00. The December Future is trading at 935.45.

BTST future tips: Buy Today at/above: 937.89, Sell tomorrow at  952.79, 960.52, 968.28 stop loss 930.25.